stockrowAbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
Follow ABBV
Alert me
AbbVie Inc. (ABBV) Current ratio
AbbVie Inc.'s current ratio at the end of the quarter to 30 September 2026 was 0.9×, up 0.2× from fiscal 2025 (0.7×). Over the past ten years it has ranged from 0.7× (fiscal 2024) to 3.2× (fiscal 2019); the current reading is higher than 18% of that period. That is below the Drug Manufacturers General industry median of 1.4× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 0.7× | 1.68% |
| FY2024 | 0.7× | (24.30%) |
| FY2023 | 0.9× | (9.50%) |
| FY2022 | 1.0× | 21.44% |
| FY2021 | 0.8× | (5.92%) |
| FY2020 | 0.8× | (73.46%) |
| FY2019 | 3.2× | 223.27% |
| FY2018 | 1.0× | (22.93%) |
| FY2017 | 1.3× | (22.94%) |
| FY2016 | 1.7× | 10.51% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 0.9× | 7.56% |
| Jun 2026 | 0.8× | 1.52% |
| Mar 2026 | 0.8× | 18.64% |
| Dec 2025 | 0.7× | (7.34%) |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| AMGN Amgen Inc. compare | 1.5× |
| PFE Pfizer Inc. compare | 1.4× |
| LLY Eli Lilly and Company compare | 1.4× |
| GILD Gilead Sciences, Inc. compare | 1.4× |
| MRK Merck & Co., Inc. compare | 1.3× |
| JNJ Johnson & Johnson compare | 1.0× |
| AZN AstraZeneca PLC compare | 1.0× |
| NVS Novartis AG compare | 0.9× |
| ABBV AbbVie Inc. | 0.9× |
| Drug Manufacturers General industry median | 1.4× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement